Fig. 7.
Appearance of antineutrophil activity in the serum of the LADII patient after L-fucose treatment.
Neutrophils purified from a healthy donor were stained with diluted (1:100) serum obtained from a healthy donor (control) or the LADII patient on day 41 of treatment (D41). Secondary antibody staining was used as control (closed histogram). Insets show immunofluorescence staining of cytospin preparations of neutrophils from the same samples used for fluorescence-activated cell-sorting (FACS) analysis.